Результаты поиска

Current options for the treatment of Paget's disease of the bone.

Paget's disease of bone (PDB) is a chronic bone remodelling disorder characterized by increased osteoclast-mediated bone resorption, with subsequent compensatory increases in new bone formation, resulting in a disorganized mosaic of woven and lamellar bone at affected skeletal sites. This disease is most often asymptomatic but can be associated with bone pain or deformity, fractures, secondary arthritis, neurological complications, deafness, contributing to substantial morbidity and reduced quality of life. Neoplastic degeneration of pagetic bone is a relatively rare event, occurring with an i

Совпадение в полном тексте источника
… Arthritis Rheum. 2003;48:2097–2099. doi: 10.1002/art.11135. 63. Merlotti D, Gennari L, Martini G, et al. Comparison of different intravenous bisphosphonate regimens for Paget’s disease of bone. J Bone Miner Res. 2007;22:1510–1517. doi: 10.1359/jbmr.070704. 64. … Arthrit Rheum. 1988;31:1142–1147. doi: 10.1002/art.1780310909. 77. Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F. Paget disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate. …

Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials.

B cell stimulating factor (BLyS) and a proliferation-inducing ligand (APRIL) are targets for novel treatments in patients with systemic lupus erythematosus (SLE). Atacicept is a recombinant, soluble fusion protein that blocks BLyS and APRIL activity. This study characterized the pharmacokinetic (PK) profile of atacicept using a population PK model and identified covariates explaining the PK variability. Total atacicept concentrations from a phase I study in healthy volunteers and two phase II studies in patients with SLE, using subcutaneous administration, were modeled using a quasi-steady-sta

Совпадение в полном тексте источника
… Arthritis Rheum. 2011;63:3918‐3930. 9. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211‐221. 10. Navarra SV, Guzmán RM, Gallacher AE, et al. … Ann Rheum Dis. 2015;74:1667‐1675. Associated Data Supplementary Materials Appendix S1 Click here for additional data file. Appendix S2 Click here for additional data file. …

Prevalence and characteristics of concomitant septic and crystal-induced arthritis: A hospital database and literature review.

BACKGROUND AND OBJECTIVES: Concomitant septic and crystal-induced arthritis is a rare condition. Failure to diagnose this condition can result in significant harm to the patient. This study aims to investigate the prevalence and characteristics of concomitant septic and crystal-induced arthritis. METHODS: A retrospective study included patients diagnosed with concomitant septic and crystal-induced arthritis confirmed by positive bacterial culture and intracellular crystals in synovial fluid of the same joint, from January 1, 2015, to July 31 ,2024. RESULTS: A total of 45 cases were defined a

Совпадение в полном тексте источника
… Ann Rheum Dis. 2015;74:1789. doi: 10.1136/annrheumdis-2015-208237. et al . –. [4] Zhang W, Doherty M, Bardin T. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. … Ann Rheum Dis. 2003;62:513. doi: 10.1136/ard.62.6.513. et al . –. [6] Weston VC, Jones AC, Bradbury N. Clinical features and outcome of septic arthritis in a single UK Health District 1982–1991. Ann Rheum Dis. 1999;58:214. doi: 10.1136/ard.58.4.214. et al . –. …

Secondary Osteoporosis and Metabolic Bone Diseases.

Fragility fracture is a worldwide problem and a main cause of disability and impaired quality of life. It is primarily caused by osteoporosis, characterized by impaired bone quantity and or quality. Proper diagnosis of osteoporosis is essential for prevention of fragility fractures. Osteoporosis can be primary in postmenopausal women because of estrogen deficiency. Secondary forms of osteoporosis are not uncommon in both men and women. Most systemic illnesses and organ dysfunction can lead to osteoporosis. The kidney plays a crucial role in maintaining physiological bone homeostasis by control

Совпадение в полном тексте источника
… Rheum. Dis. 2020;79:185. doi: 10.1136/annrheumdis-2020-eular.4539. 55. Sato M., Inaba M., Yamada S., Emoto M., Ohno Y., Tsujimoto Y. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; An observational study. J. Bone Miner. …

Prevalence of Hypovitaminosis D in Adults Presenting With Generalized Aches: A Hospital-Based Observational Study.

INTRODUCTION AND AIM: Generalized aches mean widespread musculoskeletal pain. It has various etiologies, and among them, hypovitaminosis D is one of the common causes. This study aimed to determine the prevalence of hypovitaminosis D and to identify other causes of generalized aches in adults. METHODS: This retrospective, observational, descriptive study was conducted at Nepal Medical College and Teaching Hospital (NMCTH), Kathmandu, Nepal. Records of adults presenting to the rheumatology OPD with generalized aches from January 1, 2023, to December 31, 2024, were reviewed. Serum 25(OH)D and o…

Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment.

As a systemic autoimmune disease, rheumatoid arthritis (RA) usually causes damage not only to joints, but also to other tissues and organs including the heart, kidneys, lungs, digestive system, eyes, skin, and nervous system. Excessive complications are closely related to the prognosis of RA patients and even lead to increased mortality. This article summarizes the serious complications of RA, focusing on its incidence, pathogenesis, clinical features, and treatment methods, aiming to provide a reference for clinicians to better manage the complications of RA.

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis.

Monoclonal antibodies or fusion proteins, defined as biological drugs, have modified the natural history of numerous immune-mediated disorders, allowing the development of therapies aimed at blocking the pathophysiological pathways of the disease, providing greater efficacy and safety than conventional treatment strategies. Virtually all therapeutic proteins elicit an immune response, producing anti-drug antibodies (ADAs) against hypervariable regions of immunoglobulins. Immunogenicity against biological drugs can alter their pharmacokinetic and pharmacodynamic properties, thereby reducing the

Совпадение в полном тексте источника
… Arthritis Rheum. 1998;41(9):1552–63. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. 15. Yamaguchi K, Watanabe T, Satoh T, Ishiguro M, Izawa M, Inoshiri S, et al. … Ann Rheum Dis. 2012;71(11):1914–5. doi: 10.1136/annrheumdis-2012-201544. 20. Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE, et al. …

NTP Toxicology and Carcinogenesis Studies of EMODIN (CAS NO. 518-82-1) Feed Studies in F344/N Rats and B6C3F1 Mice.

Emodin is a naturally occurring anthraquinone present in the roots and bark of numerous plants of the genus Rhamnus. Extracts from the roots … odol; frangulic acid; frangula emodin; 6-methyl- 1,3,8-trihydroxyanthraquinone; Persian Berry Lake; rheum emodin; schuttgelb; 1,3,8-trihydroxy-6-methyl-9,10- anthracenedione; 1,3,8-trihydroxy-6-methylanthraquinone; 4,5,7-trihydroxy-2-methylanthraquinone.

Disruption of the microenvironmental ecosystem in subchondral bone marrow lesions: Roles in osteoarthritis pathophysiology, pain and progression.

This narrative review explores the role of subchondral bone in the pathophysiology of osteoarthritis (OA), emphasizing the biomechanical and biochemical contributions that it makes to disease progression. A fresh perspective is presented by the authors in the form of a novel hypothesis that implicates mechano-inflammatory disruption of the bone marrow (BM) microenvironmental ecosystem (BM niche), unresolved inflammation, and fibrosis as key drivers of OA pathogenesis and pain. BMLs, detectable via magnetic resonance imaging (MRI), serve as dynamic imaging biomarkers that correlate with pain se

Совпадение в полном тексте источника
… Rheum Dis 73 7 2014 1323 1330 Jul 24553908 10.1136/annrheumdis-2013-204763 4 Safiri S. Kolahi A-A Smith E. Hill C. Bettampadi D. Mansournia M.A. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017 Ann. Rheum. … Rheum 56 12 2007 4065 4073 Dec 18050218 10.1002/art.23034 67 Blaney Davidson E.N. Vitters E.L. van der Kraan P.M. van den Berg W.B. …

Calcium-Permeable Channels Cooperation for Rheumatoid Arthritis: Therapeutic Opportunities.

Rheumatoid arthritis is a common autoimmune disease that results from the deposition of antibodies-autoantigens in the joints, leading to long-lasting inflammation. The main features of RA include cartilage damage, synovial invasion and flare-ups of intra-articular inflammation, and these pathological processes significantly reduce patients' quality of life. To date, there is still no drug target that can act in rheumatoid arthritis. Therefore, the search for novel drug targets has become urgent. Due to their unique physicochemical properties, calcium ions play an important role in all cellula…

N-Methyl Pyrrolidone (NMP) Alleviates Lipopolysaccharide (LPS)-Induced Inflammatory Injury in Articular Chondrocytes.

BACKGROUND Studies on the chondrocyte inflammatory injury are very important for understanding the pathogenesis and clinical treatment of osteoarthritis (OA). Evidence suggests that N-methyl pyrrolidone (NMP) may be used as an adjuvant therapy alongside established methods of OA treatment. This study investigated the effect of NMP on chondrocyte inflammatory injury and explored the underlying molecular mechanism. MATERIAL AND METHODS To mimic the inflammatory injury in vitro, the articular chondrocyte line ATDC5 was simulated with lipopolysaccharide (LPS). ATDC5 cells were treated with various

Совпадение в полном тексте источника
… 8 Madry H Luyten FP Facchini A Biological aspects of early osteoarthritis Knee Sung Sports Traumatol Arthrosc 2012 20 407 22 10.1007/s00167-011-1705-8 22009557 9 Rolauffs B Rothdiener M Bahrs C Onset of preclinical osteoarthritis: The angular spatial organization permits early diagnosis Arthritis Rheum … resistance to intracellular pathogens Immunol Lett 1994 43 87 94 7537721 10.1016/0165-2478(94)00158-8 33 Brechter AB Lerner UH Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of Cyclooxygenase 2, resulting in increased RANKL expression Arthritis Rheum …

A case of renal damage induced by cryoglobulinemia associated with Monoclonal Gammopathy of Renal Significance.

BACKGROUND: Cryoglobulins are abnormal immunoglobulins present in circulation, capable of precipitating at lower temperatures and redissolvi … nd renal insuff iciency. Laboratory findings revealed a decrease in serum complement C4, a positive rheumatoid factor, and the presence of an IgMκ monoclonal immunoglobulin in serum immunofixation electrophoresis. Bone marrow biopsy revealed a plasma cell proportion of 2%. Renal biopsy analysis demonstrated membranoproliferative glomerulonephritis under …

Leukemias in the Context of Rheumatoid Arthritis: Shared Pathways and Clinical Perspectives.

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by systemic inflammation, progressive joint destruction, and increased risk of malignancies, particularly hematological cancers such as leukemias. RA patients appear to have a higher incidence of leukemias, suggesting a possible association between the two conditions. This association is driven by shared pathogenic mechanisms, including chronic inflammation, immune dysregulation, and genetic predispositions. Pro-inflammatory cytokines, notably tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6), play a crucial ro…

Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Monoclonal antibodies (mAbs) have become one of the most important classes of biopharmaceutical products, and they continue to dominate the universe of biopharmaceutical markets in terms of approval and sales. They are the most profitable single product class, where they represent six of the top ten selling drugs. At the beginning of the 1990s, an in vitro antibody selection technology known as antibody phage display was developed by John McCafferty and Sir. Gregory Winter that enabled the discovery of human antibodies for diverse applications, particularly antibody-based drugs. They created c

Multiple myeloma presenting with amyloid arthropathy as the first manifestation: Two case reports.

BACKGROUND: Multiple myeloma (MM) can be accompanied by amyloidosis, which occurs in a small number of patients and is characterized by deposition of light chains in the joints, leading to multiple myeloma-associated amyloid arthropathy (MAA). As a rare complication of MM, clinical manifestations of MAA are often similar to those of rheumatoid arthritis, and the two are easily confused. CASE SUMMARY: In recent years, our center treated two patients of MM with amyloid arthropathy as the first manifestation, both of whom presented with polyarthritis. After treatment for MM, both patients achiev…

Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sjögren's syndrome: nationwide population-based cohort study.

OBJECTIVE: The aim of this study was to explore whether patients with Sjögren's syndrome (SS) were susceptible to bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) after tooth extraction in the entire population of Taiwan. DESIGN: A nationwide population-based retrospective cohort study. SETTING: Data were extracted from Taiwan's National Health Insurance Research Database (NHIRD). METHODOLOGY: Medical conditions for both the study and control group were categorised using the International Classification of Diseases, 9th Revision. ORs and 95% CIs for associations between SS and o

Совпадение в полном тексте источника
… Ann Rheum Dis 2002 ; 61 : 554 – 8 . 10.1136/ard.61.6.554 12006334 PMC1754137 5. Mavragani CP , Moutsopoulos HM The geoepidemiology of Sjögren’s syndrome . Autoimmun Rev 2010 ; 9 : A305 – A310 . 10.1016/j.autrev.2009.11.004 19903539 6. … Ann Rheum Dis 1999 ; 58 : 382 – 5 . 10.1136/ard.58.6.382 10340964 PMC1752901 10. Cheng CL , Kao YH , Lin SJ , et al Validation of the national health insurance research database with ischemic stroke cases in Taiwan . Pharmacoepidemiol Drug Saf 2011 ; 20 : 236 – 42 . 10.1002/pds.2087 21351304 11. …

Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients.

BackgroundFew studies addressing the safety and efficacy of biological therapy (BT) or apremilast (APR) in patients with psoriasis with a history of hematologic malignancy (HM) exist.AimTo describe the tolerance and efficacy of BT and APR in moderate-to-severe psoriasis in patients with a history of in-remission or evolving HM.MethodologyA retrospective, multicenter chart review of the tolerance and efficacy of BT or APR in patients with moderate-to-severe psoriasis and a clinical history of in-remission or evolving HM.ResultsTwenty-one patients with severe psoriasis and a history of HM were i

Совпадение в полном тексте источника
… Ann Rheum Dis . 2011 ; 70 ( 11 ): 1895 – 1904 . doi: 10.1136/ard.2010.149419 21885875 23. Wolfe F , Michaud K . Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study . … Ann Rheum Dis . 2009 ; 68 ( 7 ): 1136 – 1145 . doi: 10.1136/ard.2008.091025 18753157 26. LE BLAY P , Mouterde G , Barnetche T , Morel J , Combe B . …

Identification and validation of CKAP2 as a novel biomarker in the development and progression of rheumatoid arthritis.

BACKGROUND: Rheumatoid arthritis (RA) is a common chronic joint disease. However, many patients exhibit inadequate responses to treatment due to disease heterogeneity. Identifying novel biomarkers for RA is crucial for advancing molecular diagnosis and identifying potential therapeutic targets. METHODS: Synovial tissue transcriptome data from RA patients and healthy controls were obtained from the GEO database. Differentially expressed gene (DEG) analysis, functional enrichment analysis, and weighted gene co-expression network analysis (WGCNA) identified key gene modules in RA. Machine learni…

A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs.

Productivity costs can strongly impact cost-effectiveness outcomes. This study investigated the impact in the context of expensive hospital drugs. This study aimed to: (1) investigate the effect of productivity costs on cost-effectiveness outcomes, (2) determine whether economic evaluations of expensive drugs commonly include productivity costs related to paid and unpaid work, and (3) explore potential reasons for excluding productivity costs from the economic evaluation. We conducted a systematic literature review to identify economic evaluations of 33 expensive drugs. We analysed whether eva

Совпадение в полном тексте источника
… Arthritis Rheum. 2009;61:291–299. doi: 10.1002/art.24169. 34. Norum J, Holtmon M. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective? Acta Oncol. 2005;44:735–741. doi: 10.1080/02841860500247503. 35. … Rheum. Dis. 2004;63:4–10. doi: 10.1136/ard.2003.010629. 50. Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. …

Dermatologic Emergencies

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Rheum Dis Clin North Am. 1995;21(4):911–47. 49. Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology. 2010;56(1):3–23. doi: 10.1111/j.1365-2559.2009.03443.x. 50. De Groot K, et al. … Arthritis Rheum. 2005;52(8):2461–9. doi: 10.1002/art.21142. 51. Sigurdsson V, Steegmans PH, van Vloten WA. The incidence of erythroderma: a survey among all dermatologists in The Netherlands. J Am Acad Dermatol. 2001;45(5):675–8. doi: 10.1067/mjd.2001.116224. 52. Pal S, Haroon TS. …